Novavax phase 3 results. Uncover the latest research and company analysis to empower your investments. Jun 12, 2025 · Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings. S vaccine (Johnson & Johnson/Janssen), efficacy against moderate-to-severe Covid-19 among 6576 Aug 31, 2022 · On Feb. Feb 26, 2026 · Novavax, Inc. , June 11, 2025 /PRNewswire/ --Novavax, Inc. Feb 2, 2024 · Developed by University of Oxford and Serum Institute of India, the vaccine contains Novavax’s saponin-based Matrix-M™ adjuvant. Novavax Inc has announced initial results from its phase 3 clinical trial evaluating its COVID-19–influenza combination vaccine (CIC) and a stand-alone trivalent influenza vaccine candidate (tNIV) in older adults. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alonetrivalent hemagglutinin nanoparticleseasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu May 5, 2021 · In a large, multinational, phase 3 trial evaluating the efficacy of a single dose of the Ad26. Read the latest healthcare, biotech, and pharmaceutical stock news and analysis. Jun 30, 2021 · RELEASE: Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in @NEJM, Demonstrating High Levels of Efficacy of #COVID19 Vaccine bit. 7 percent. AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Results: A total of 911 participants were randomized between July 11 and 13, 2022, with 905 being assessed for safety and 848 for immunogenicity. 28, 2022, Novavax released results from a six-month follow up on its Phase 3 clinical trial in the United Kingdom. com and LinkedIn for more information. Feb 27, 2026 · Opportunities and Catalysts Sanofi Milestone: Sanofi is expected to launch its own Phase 3 trial using Novavax tech in 2026, which would trigger a $125 million milestone payment to Novavax. Jun 11, 2025 · Please visit novavax. COV2. May 2026 Data: Completion of the CIC Lot Consistency Study will be a major de-risking event. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. Sep 22, 2023 · These responses were compared for the three lots, and for participants with primary series with or without a prior booster dose of the mRNA-1273, BNT162b2, Ad26. The R21/Matrix-M vaccine is one of several ongoing collaborations involving Novavax’s adjuvant technology, including additional research in malaria and other infectious diseases in both humans and animals. Novavax is a biotech company advancing health through R&D and partnerships. The vaccine’s efficacy against Covid waned slightly to 82. Jan 20, 2026 · Listing of latest press releases and statements by Novavax. S, or NVX-CoV2373 COVID-19 vaccines. . Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for its CIC and stand-alone influenza vaccine to be used with a partner in a registrational Phase 3 program, are forward-looking Dec 15, 2021 · We conducted this phase 3, randomized, observer-blinded, placebo-controlled trial at 113 clinical sites in the United States and 6 in Mexico to evaluate the efficacy and safety of NVX-CoV2373. Dec 10, 2024 · The randomized Phase 3 trial builds on positive Phase 2 data and aims to further evaluate the immunogenicity and safety of a combination of Novavax's updated 2024-2025 COVID-19 vaccine, trivalent nanoparticle stand-alone seasonal influenza vaccine candidate and patented saponin-based Matrix-M adjuvant relative to separate administrations of Jun 11, 2025 · Novavax continues to pursue partnering opportunities to advance further development of these programs GAITHERSBURG, Md. Novavax, today announced positive initial results from the Phase 3 trial evaluating its COVID-19-Influenza Combination (CIC) vaccine and the stand-alone trivale Jun 11, 2025 · Summary Summary On June 11, 2025, Novavax Inc (NVAX, Financial) released promising results from the initial cohort of its Phase 3 trial for the COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines. ly/3qGPwaH 💬50 Feb 27, 2026 · Opportunities and Catalysts Sanofi Milestone: Sanofi is expected to launch its own Phase 3 trial using Novavax tech in 2026, which would trigger a $125 million milestone payment to Novavax. Jan 27, 2025 · An updated search to include all publications up to July 12, 2024, identified the results of a completed phase 3 trial, reporting a vaccine efficacy of NVX-CoV2373 of 76·3% against asymptomatic infections measured by nucleocapsid seroconversion among adults. xmwh wrycboz qxbnradah mdzu zciix jyu ldo gpmsd mafp jnpsh